JUMPCAN(SH:600566)2022-04-15 16:00Financial Performance - The company's operating revenue for 2021 was CNY 7,630,510,000.18, representing a 23.77% increase compared to CNY 6,164,974,167.54 in 2020[18]. - The net profit attributable to shareholders for 2021 was CNY 1,719,175,931.11, a 34.60% increase from CNY 1,277,212,486.54 in 2020[18]. - The basic earnings per share for 2021 was CNY 1.94, up 26.80% from CNY 1.53 in 2020[20]. - The company's total assets at the end of 2021 were CNY 12,131,036,777.90[19]. - The net cash flow from operating activities for 2021 was CNY 1,894,329,392.98, a 6.32% increase from CNY 1,781,691,163.33 in 2020[18]. - The company's net assets attributable to shareholders increased by 17.44% to CNY 9,116,878,404.95 at the end of 2021[18]. - The diluted earnings per share for 2021 was CNY 1.91, reflecting a 24.84% increase from CNY 1.53 in 2020[20]. - The weighted average return on equity for 2021 was 20.46%, an increase of 0.57 percentage points from 19.89% in 2020[20]. - The quarterly operating revenue for Q4 2021 was CNY 2,221,444,724.92[21]. - The net profit attributable to shareholders for Q4 2021 was CNY 447,204,183.33[21]. Dividend and Profit Distribution - The profit distribution plan for 2021 proposes a cash dividend of 6.80 CNY per 10 shares, totaling approximately 604 million CNY (including tax) based on the total share capital of 888,276,131 shares as of March 31, 2022[3]. - The company distributed a cash dividend of 0.45 CNY per share, totaling 399,716,086.05 CNY for the 2020 fiscal year[116]. - The company has a cash dividend policy that stipulates a minimum of 30% of the average distributable profit over the last three years should be distributed as cash dividends[116]. Corporate Governance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants, ensuring the authenticity and completeness of the financial report[2]. - The board of directors and supervisory board members have all attended the board meeting, ensuring proper governance[2]. - The company ensures that all shareholders, especially minority shareholders, can fully exercise their voting rights during meetings[85]. - The company has established a designated board secretary responsible for information disclosure and investor relations management, ensuring timely and accurate information dissemination[85]. - The company strictly adheres to the requirements of the Company Law, Securities Law, and the Corporate Governance Guidelines, ensuring compliance with regulatory standards[85]. Risk Management - There are no significant risks that could materially affect the company's operations during the reporting period[5]. - The company has confirmed that there are no non-operational fund occupations by controlling shareholders or related parties[4]. - The company has not violated decision-making procedures in providing guarantees to external parties[4]. - The company has outlined potential risks that may adversely affect its future development strategies and operational goals[5]. - The report includes a forward-looking statement risk declaration, indicating that future plans do not constitute a substantive commitment to investors[4]. Research and Development - The company’s R&D expenses surged by 114.74%, amounting to RMB 523.44 million, indicating a strong commitment to innovation[34]. - The company is committed to increasing R&D investment to enrich its product line and enhance operational performance[26]. - The company is focused on the research and development of generic drugs with clinical advantages to gain product competitiveness[26]. - The company has established a research team for traditional Chinese medicine formula granules and is actively participating in quality standard formulation[27]. - The company’s R&D investment accounted for 7.14% of total revenue, with capitalized R&D expenses making up 3.89% of the total[48]. Market and Product Development - The company entered into 4 product introduction or cooperation agreements to enhance its product line[24]. - A strategic cooperation agreement was signed with Tianjing Biotechnology for the development and commercialization of long-acting recombinant human growth hormone, with an initial payment of CNY 224 million[24]. - The company achieved a total operating revenue of RMB 7,630.51 million, representing a year-on-year growth of 23.77%[34]. - The company is focusing on digital marketing and e-commerce to expand its sales channels[24]. - The company plans to deepen marketing management and optimize sales channels to improve sustainable development and profitability[26]. Environmental Compliance - The company is listed as a key pollutant discharge unit, with major pollutants including COD and ammonia nitrogen, and has reported compliance with discharge limits[124]. - The company’s wastewater discharge includes a total of one discharge outlet, with specific monitoring data indicating compliance with environmental standards[124]. - The company has implemented proper disposal of solid waste generated during production, ensuring compliance with regulations[128]. - The wastewater treatment facility has a design capacity of 4,500 tons/day for general wastewater and 600 tons/day for raw material wastewater, ensuring compliance with discharge standards[133]. - The company has established a comprehensive pollution prevention facility that operates effectively, ensuring all emissions meet the required standards[133]. Shareholder Structure and Changes - The total number of common shareholders as of the end of the reporting period is 55,196, an increase from 53,432 at the end of the previous month[177]. - Jiangsu Jichuan Holding Group Co., Ltd. holds 416,757,360 shares, representing 46.92% of total shares, while Tibet Jichuan Investment Management Co., Ltd. holds 100,000,000 shares, representing 11.26%[178]. - The top three shareholders include Jiangsu Jichuan Holding Group Co., Ltd., Tibet Jichuan Investment Management Co., Ltd., and Cao Longxiang, with Cao holding 46,838,458 shares, or 5.27%[178]. - The company’s shareholder structure saw significant changes with the release of limited sale shares, impacting the overall share distribution[176]. - The company’s ordinary shares now consist entirely of unrestricted circulating shares following the release of limited sale shares[176]. Financial Management - The total amount of entrusted financial management using raised funds reached CNY 1,257,990,000, with an unexpired balance of CNY 1,115,000,000 as of December 31, 2021[160]. - The company has invested CNY 560,000,000 of its own funds in entrusted financial management, with the entire amount still unexpired[160]. - The annualized return rate for various financial products ranges from 3.05% to 3.80%[164]. - The company reported an investment income of 48.72 million yuan (including tax) from entrusted financial management as of December 31, 2021[167]. - The company has not recognized any impairment provisions for entrusted loans or financial products[169].